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This paper estimates the costs of introducing several AIDS-related prevention 
and treatment programmes in South Africa.1  Our approach combines detailed 
information about the costs of implementing these interventions with 
demographic projections of their impact.  Information about prices, wages 
and other cost components is drawn from a range of primary and secondary 
sources.     
 
Johnson and Dorrington’s (2002) modelling of the demographic impact of 
four AIDS-related health interventions is a central input into our costing 
exercise.  We begin the paper with an overview of the key characteristics and 
results of their ASSA2000 ‘Interventions Model’.2  The paper then discusses 
the cost components of each of these interventions.  We draw attention to the 
additional costs not considered in our primary analysis, and to the effect of 
antiretroviral medicine prices on the total cost of providing highly active 
antiretroviral therapy (HAART) to those who need it.   
 
HAART is expensive, but the net costs to government are significantly lower 
than the direct costs of providing HAART.  This is because people on 
HAART experience fewer opportunistic infections (OIs) – thereby saving the 
government the costs of treating those OIs.  We estimate these ‘hospital costs 
averted’, provide a brief discussion of the savings associated with fewer 
orphans, and then conclude with a calculation of the cost of prevention and 
treatment programmes as a percentage of GNP.  
 
 
                                          
1  The spreadsheets used for the cost calculations are available upon request from Nathan 
Geffen at nathan@tac.org.za.  Numerous people provided essential information for this 
research. Thank you to Leigh Johnson, Rob Dorrington, Zackie Achmat, Neva Makgetla, 
Mark Heywood, Cecille Dehoper, Marta Darder, Toby Kasper, Eric Goemaere, Catherine 
Orrell, Robin Wood, Dikeledi Tshukudu, Fareed Abdullah, Marc Cotton, Linda-Gail 
Bekker, Jonathan Berger, David Coetzee, Barbara Kaparkis, Glenda Gray, Karen 
Kallmann, Stephen Gelb, staff at LifeLine and staff at Aid for AIDS. Leigh Johnson’s 
contribution to this work has been especially critical. 
2  The ASSA2000 model is South Africa’s premiere demographic model.  It, and the 
Interventions Model developed by Johnson and Dorrington, can be downloaded (free of 
charge) from the Actuarial Society of South Africa website:   
www.assa.org.za/aidsmodel.asp.   
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The Demographic Modelling 
 
Johnson and Dorrington (2002) analyse the demographic impact of the 
following four health interventions:  voluntary counselling and testing 
(VCT); mother-to-child transmission prevention (MTCTP) of HIV; better 
management of sexually transmitted infections (STIs) and highly active anti-
retroviral therapy (HAART).  The key aspects of these interventions are 
highlighted in Table 1.       
 
 
Table 1: Interventions Modelled in the ASSA2000 Interventions Model  
Prevention 
Interventions 
• VCT is offered before and after HIV testing. Counselling on 
safer sex is included. 
• MTCTP is implemented using the HIVNET 012 protocol (Guay 
et al., 1999). Fifty percent of women on this programme use 
formula milk. 
• Syndromic management guidelines become the norm in the 
private sector. Acyclovir is used to treat patients with Herpes 
blisters. Medicine shortages at public STI clinics are eliminated.  
Private practitioners can purchase medicines for treating STIs at 
state tender prices, therefore these medicines become more 




Antiretroviral therapy using three or more medicines is made 
available to adults with AIDS defining symptoms or whose CD4 
counts are below 200/µl. For children, therapy is initiated if the 
child is experiencing AIDS-defining symptoms, according to the 
CDC Clinical Staging System for Children, or if their CD4 
percentage is below 15 percent. 
Source:  Johnson and Dorrington (2002) 
 
 
We refer to VCT, MTCTP and managing STIs as ‘prevention’ interventions 
because their primary function is to reduce transmission of HIV.  HAART is 
referred to as a ‘treatment’ measure because its primary function is to 
improve the health of people with HIV/AIDS.  This distinction is, of course, 
somewhat arbitrary because prevention interventions can improve health (e.g. 
through counselling), and treatment interventions can reduce HIV 
transmission by lowering viral loads and encouraging people to be tested and 
counselled about safer sexual practices.       
 
Johnson and Dorrington (2002) model three different intervention scenarios.  
Scenario One assumes that none of the interventions are implemented and 
thus no direct additional costs are incurred.  Scenario One broadly resembles 
the current situation in the public sector.  The only AIDS-related cost is the 
treatment of OIs of people living with AIDS.  Hospitalisation costs rise over 
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time under Scenario One as HIV morbidity (i.e. ill-health) in the general 
population increases.  Scenario Two assumes that the government introduces 
various prevention measures, and Scenario Three also includes a treatment 
intervention (HAART).  Table 2 summarises the components of the different 
scenarios.   
 
 
Table 2: Interventions modelled under each scenario 
 VCT MTCTP STI HAART 
Scenario One (treatment of opportunistic 
infections only) 
No No No No 
Scenario Two (prevention interventions and 
treatment of opportunistic infections) 
Yes Yes Yes No 
Scenario Three (Treatment with antiretroviral 
therapy, prevention and treatment of opportunistic 
infections) 
Yes Yes Yes Yes 
Source:  Johnson and Dorrington (2002) 
 
 
The ASSA2000 Interventions Model assumes that the various interventions 
are phased in over time.  Table 3 displays the percentage of the population 
assumed to have access to the interventions over time.  We refer to these as 
the phase-in rates.  The phase-in rates are not increased beyond 90 percent 
since few public health interventions are rolled out to more than 90 percent of 
the population using the public health system. 
 
 
Table 3: Percentage of population for which the interventions are 
available over time 
 2001      2002 2003 2004 2005 2006
MTCTP 10% 30% 50% 70% 85% 90% 
All other interventions 0% 20% 40% 60% 80% 90% 
Source:  Johnson and Dorrington (2002) 
 
 
According to the ASSA2000 Interventions Model, life expectancy will 
improve significantly if prevention interventions are introduced (Scenario 
Two), and dramatically if treatment and prevention interventions (Scenario 
Three) are introduced.  According to Scenario One, life expectancy is likely 
to be just over 40 years in 2008, whereas under Scenario Three, people can 
expect to live 8-10 years longer (see Figure 1).  This improvement in life 
expectancy is a function of the life-prolonging impact of HAART and lower 
rates of HIV transmission (arising from MTCTP, lower rates of STIs and 
safer sexual practices following VCT).       
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Figure 1: Life-expectancy under the three scenarios (from Johnson 
and Dorrington, 2002) 
 
 
Over 2.5 million new HIV infections and slightly fewer than three million 
AIDS deaths are avoided under Scenario Three compared with Scenario One.  
In Scenario Two, over 1.5 million new HIV infections are avoided, but fewer 
than 500 000 AIDS deaths are prevented (see Figure 2).   
 
 


























Figure 2: HIV infections and AIDS deaths averted, July 2002 to June 
2015 (from Johnson and Dorrington, 2002) 
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Under Scenario One, about three million maternal orphans (those who lose 
their mother) under the age of 18 are produced by the year 2015.  Under 
Scenario Three, this number is reduced by approximately 700 000.  Double-
orphans (i.e. those who have lost their father and mother) are reduced from 




Table 4: Number of People Accessing Interventions in Scenario Three 
  2007   2010 2015
MTCTP 935 000 903 000 883 000 
VCT (HIV-)3 283 000 273 000 277 000 
VCT (HIV+) 139 000 94 000 59 000 
Adult HAART 1 147 000 1 941 000 2 317 000 
Paediatric HAART 110 000 157 000 166 000 
STI Treatments 10 505 000 8 264 000 6 612 000 
Public Sector STI Treatments 4 202 000 3 306 000 2 645 000 
Source: Projections from the ASSA2000 model provided by Leigh Johnson 
 
 
Table 4 reports the projected number of people using the various 
interventions modelled in Scenario Three (treatment and prevention).  We 
use these estimates in our calculation of the total cost to the government of 
providing the interventions in Scenario Three.     
 
 
The Cost of Interventions 
 
Information about the costs of the interventions was obtained from various 
primary and secondary sources.  Interviews were conducted with doctors and 
budget administrators at the following institutions:  Somerset Hospital, Chris 
Hani Baragwanath Hospital, Tygerberg Hospital, Groote Schuur Hospital, the 
Medecins Sans Frontieres pilot antiretroviral project in Khayelitsha, the 
Western Cape Department of Health, Black Sash, Pinetown Child Welfare 
and personnel in the Government administrative offices in Pretoria.  Nearly 
all price data (including anti-retroviral medication) was collected between 
September 2001 and October 2002.  Data from earlier periods was adjusted 
upwards to account for inflation.  All monetary amounts projected into the 
future are given in 2002 prices. 
 
                                          
3 This is the number of HIV-negative people who receive VCT.  The next row gives the 
number who are HIV-positive.  More personnel time is spent with HIV-positive patients. 
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The largest factor in the cost of Scenario Three is the price of anti-retroviral 
medication which varies according to exchange rate fluctuations and 
conditions in pharmaceutical markets.  Greater stability of prices could be 
achieved through local production of generic anti-retrovirals, and importation 
of medicines from countries with currencies that move in sync with the Rand. 
 
 
Common Cost Factors 
 
A number of cost factors, such as personnel and HIV testing, are common to 
all interventions. These are presented in Tables 5 and 6.  LifeLine (a non-
governmental organisation providing counselling services) reports that 
counsellors spend one day a week with their supervisors, therefore, on 
average, only 14 days per month are spent counselling.4  We make this 
assumption in our costing model and assume further that each working day 
entails five hours of counselling time.  This is consistent with information 
provided by the Western Cape Department of Health, but should probably be 
regarded as a pessimistic estimate of potential counsellor productivity.  
 
 
Table 5: Salaries of staff working in different health interventions 
Salaries (includes benefits and the cost of ongoing training) 
Employee Monthly Source 
Counsellor supervisor R7,500 Galbraith and Bennish, 2001 
Doctor R18,000 Medecins Sans Frontieres estimate 
Manager / Project supervisor R12,000 Johnson et al., Jan 2001, p.53 
Nurse R10,000 Johnson et al., Jan 2001, p.53 
Counsellor R2,500 Galbraith and Bennish, 2001 
 
 
Table 6: Productivity of key health staff 
Staff Productivity 
Employee Hours Productive per Day Workdays per Month* 
Counsellors 5 14 
Nurses 8 18 
Doctors 8 18 
* Includes only active workdays – i.e. leave is deducted 
 
 
We obtained estimates for nursing and counselling costs from a number of 
sources, but decided to err on the side of caution by using those on the higher 
                                          
4 Personal communication with LifeLine. 
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end of the scale.  Counselling costs in some provinces are substantially lower 
than the ones used here.  As such, the above figures should probably be 
viewed as estimates of counselling costs in properly functioning facilities.  
Table 7 documents the additional parameters we used in the costing of VCT 
and MTCT programmes.   
 
 
Table 7:  Additional Parameters Used in Costing Counsellors 
Counsellor Specific Values 
Factor Value Source 
Average Time Period Counsellors 
Work in an Intervention Before 
Leaving 
12 months Simplifying assumption for calculation 
purposes, but probably pessimistic 
Recruitment/Counsellor R1,029 Galbraith and Bennish, 2001 
Training per Counsellor R3,286 Galbraith and Bennish, 2001 
 
 
The MTCTP and VCT interventions include HIV tests. The VCT and 
HAART interventions include CD4 tests. The cost factors of these tests are 
presented in Table 8.  We assume that patients undergoing HIV tests are 
given a rapid Determine test.  Those patients who are found to be HIV-
positive then undergo a Smartcheck test.  All patients whose initial results are 
indeterminate (assumed to be 5 percent of those tested) then undergo an Elisa 
test.  Note that some provinces receive donated test kits (e.g. Western Cape), 
so there is reason to believe our estimated costs are probably on the high side.   
 
 
Table 8: Costs of HIV antibody and CD4 tests 
Cost of Tests   
Factors Value Source 
Cost of Rapid Test R10.70 
Cost of Smartcheck R6.25 
Cost of Elisa R29.10 
Indeterminacy Rate 5% 
Personal communication with 
Western Cape Department of 
Health (2001) 
CD4 Test R82.40 D. Glencross (NHLS) 
 
 
The total cost of the VCT programme includes personnel costs and HIV 
testing costs.  Total costs per patient for personnel and testing depend on HIV 
status.  The costing exercise assumes that those who test HIV-positive will 
then undergo regular CD4 tests.  An adjustment is included to allow for 
patients who drop out of the programme (see Table 9).  Patients spend time 
with nurses and counsellors on an individual basis and also participate in 
group counselling sessions consisting of about 20 patients (see Table 10).   
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Table 9: Patient monitoring factors in VCT intervention 
Patient Monitoring Value 
Follow-up Rate First Visit 75% 
Subsequent Follow-up Rate 95% 
Number of CD4 Tests per Patient per Year 1 
Source:  Medecins Sans Frontieres  in Khayelitsha, Groote Schuur Hospital 
 
 
Whereas the ASSA2000 Interventions Model assumes individual counselling 
(Johnson and Dorrington, 2002), we assume an initial group counselling 
session followed by an individual counselling session.  We further assume 
that the demographic impact of the VCT intervention is the same as that 
projected by the ASSA2000 Interventions Model.  
 
 
Table 10: Time spent with patients in VCT intervention 
Personnel Time Value 
Nursing Time per Patient 1st Visit 3 minutes 
Nursing Time per Patient 2nd Visit 3 minutes 
Counselling Session Lengths 45 minutes 
Length of Group Sessions 2 hrs 
Patients per Group 20 
1st Visit (Group)  
2nd Visit (Individual) 45 minutes 
3rd Visit (Group)  
4th Visit (Group)  
Wastage Factor 5% 
Source: Medecins Sans Frontieres Programme in Khayelitsha 
 
 
The Cost of an STI Intervention 
 
Table 11 describes the symptoms and associated prescribed medicines 
associated with a syndromic management STI programme.5  We obtained the 
numbers of patients suffering from each type of symptom (as well as the 
percentage of cases that are expected to be treated correctly) from the 
ASSA2000 Interventions Model.  Of those cases of ulcers that are actually 
caused by herpes simplex virus-2 (HSV-2), 20 percent are expected to be 
misdiagnosed.  These patients will receive the medicines prescribed for 
patients suffering from ulcers not caused by HSV-2. 
                                          
5 In practice, different medicines would be prescribed to pregnant women, but we do not 
take this into account here. 
 8
Table 11: Medicines prescribed for the syndromic management of 
sexually transmitted infections 














Discharge Yes Yes     
Ulcers (not 
HSV-2) 
   Yes Yes  
Ulcers due to 
HSV-2 
     Yes 
Female 
Discharge Yes Yes Yes    
Ulcers (not 
HSV-2) 
    Yes Yes  
Ulcers due to 
HSV-2 




Table 12 presents the medical prescriptions and prices used in the costing 
exercise.  The cost per patient is a function of the unit price per pill (implicit 
in the ‘Medicine Costs’ column) multiplied by the number of pills specified 
in the ‘Prescription’ column. 
 
 
Table 12: Medicine costs and dosages for STI intervention 
Syndromic Management: Medicine Costs 
Medicine Prescription Medicine Costs Cost per 
Patient 
Source 
Acyclovir 400mg 3 times a 
day for 5 days 
Price of pack of 25, 




500mg 3 times a 
day for 5 days  
Price of pack of 100, 
250mg pills is R34.05 
R10.22 
Ciprofloxacin 500mg once Price of pack of 10, 
500mg pills is R57.32 
R5.73 
Doxycycline 100mg twice daily 
for 7 days 
Price of pack of 100, 
100mg  pills is R10.90
R1.53 
Metronidazole 400mg twice daily 
for 5 days 
Price of pack of 500, 











ones as of 
the first 
quarter of 












Table 13: Time spent on patient consultations in STI intervention 
Personnel Consultation Doctor Nurse Counsellor Source 
Time to Diagnose and Treat 










B. Kaparkis and D. 
Coetzee 
Ratio of Patients Seen by 
Doctors to Nurses 
1 : 5   Assumption 
Extra Diagnosis and 
Treatment Time for Females 
20%   Assumption 
 
 
Research suggests that diagnosis and treatment of females takes longer than 
that of males.  In order to compensate for this, all times spent by medical 
personnel with female patients were inflated by 20 percent.  Diagnosis and 
treatment time is assumed to be shorter for doctors than for nurses, and we 
assume that one in six patients is treated by a doctor rather than a nurse.   
 
 
The Costs of Preventing Mother-to-Child Transmission of HIV 
 
 
Table 14: Various factors affecting the cost of MTCTP 
Medicines, Nutrition, Uptake 
Factors Values Source 
Percentage of HIV+ uptake ARV 100% Communication with WC DOH 
Cost of NVP/mother-child R6.006 Galbraith and Bennish, 2001 
Cost of formula milk per month R83.20 WC DOH Budget for an MTCTP Site 
No. of months of formula milk 6 WC DOH Budget for an MTCTP Site 
Uptake % of formula milk 50% This has been obtained by multiplying the 
percentage of households with access to 
running water by the uptake rate of formula 
milk in the Paarl Maternity Obstetrics Unit.7 
Transmission rate at birth (no 
ARV) 
25% ASSA2000 (based on synthesis of a number 
of studies) 
Transmission rate due to 
breastfeeding 
10% ASSA2000 (based on synthesis of a number 
of studies) 
Nevirapine intrapartum reduction 
rate 
47% Guay et al., 1999 
                                          
6 We obtained varying estimates of this cost ranging from R6 to as high as R21.  However, 
given that a number of provinces now receive this medicine as part of a donation, we 
opted for the lower end of the range of estimates.   
7 We assume that the uptake rate in the Paarl Maternity Obstetrics Unit is typical of a fully 
implemented MTCTP programme in an area where most people have access to running 
water. 
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Our costing of the MTCTP intervention is the most detailed of the costing 
exercises presented in this paper.  The number of pregnant women attending 
maternity obstetrics units, the seroprevalence rate expected amongst these 
women and a phase-in rate for the programme are given by the ASSA2000 
Interventions Model.  Table 14 lists the uptake rates, drug costs and formula 
milk costs.   Table 15 details time spent by personnel with patients.  We 
assumed that children born to HIV-positive women are given cotrimoxazole 




Table 15: Time spent by personnel with patients for MTCTP 
intervention 
Personnel Time With Patients   
Factors Values Source 
Pre-test Counselling/woman 30 minutes 
Post-test Counselling/HIV+ woman 45 minutes 
Post-test Counselling/HIV- woman 20 minutes 
Communication with Western 
Cape Department of Health 
 
Pre-test Counselling for child test 30 minutes 
Post-test Counselling child test (-) 30 minutes 
Post-test Counselling child test (+) 45 minutes 
Communication with Western 
Cape Department of Health and 
others 
Nurse time per woman 15 minutes Communication with Medecins 
Sans Frontieres and others 
Additional Nurse time per HIV+ woman 10 minutes Communication with Medecins 
Sans Fronteires  and others 
Nurse time per child born to HIV+ 
woman 
25 minutes Assumption 
 
 
Table 16: Cotrimoxazole cost factors for MTCTP intervention 
Cotrimoxazole 
Factors Values Source 
Follow-up Rate of Babies at 18 Months 100% Assumption 
Cost of Cotrimoxazole per Month R2.28 Communication with Western Cape 
Department of Health 
Months of Cotrimoxazole per Child 18 Assumption 
Cotrimoxazole Uptake Rate 100% Assumption 
 
 
The costs of hiring counsellors, coordinators8 and counsellor-supervisors are 
also included in the calculation, as are the costs of technical assistance and 
the renovations of counselling rooms.  All such costs are apportioned on a per 
                                          
8  We assume that one counsellor co-ordinator manages two MTCTP sites. 
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site basis.  A site typically consists of more than one clinic and is assumed to 
cater for 5 000 pregnancies per year.  Certain cost categories are included on 
both a start-up and annualised basis.  However, start-up costs are not all 
incurred in the first year.  These are also phased in, but differ from annualised 
costs in that they are incurred only once.  
 
 
Table 17: Staff, management and infrastructure costs for MTCTP 
intervention 
Staffing and Management 
Factor Start-up Annualised Source 
Site Size  5,000 WC DOH MTCTP Site Budget & Galbraith 
and Bennish, 2001 
Counsellor 
Supervisor per Site 
 0.5 Calculation based on  number of supervisors 








The Costs of HAART 
 
In our costing of the HAART intervention, we distinguish between adult and 
paediatric programmes and consider three main cost components:  drug costs, 
monitoring costs and personnel costs.  We apply these to the number of 
people on HAART (as projected by the ASSA2000 Interventions Model).   
 
The ASSA2000 Interventions Model projects the number of people in each 
stage of HIV (as defined by the World Health Organisation (WHO).  Johnson 
and Dorrington (2002) made the following assumptions when modelling the 
demographic impact of providing HAART.     
• Triple-drug antiretroviral therapy is made available to adults with 
AIDS defining illnesses or whose CD4 count is below 200/µl.  
• In the first six months of treatment, there is an 8.2 percent chance of 
death due to AIDS and a 9.1 percent chance of ceasing treatment due to 
adverse side-effects.  
• In each subsequent year there is a 5.8 percent chance of death due to 
AIDS and a 5.8 percent chance of ceasing treatment due to adverse side-
effects. 
• When patients cease treatment they are assumed to experience a level 
of mortality compared to antiretroviral naïve patients, i.e. they go back 
to the stage they were at the onset of HAART.  
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• The reduction in incidence of AIDS-related morbidity for patients on 
HAART is 75 percent. 
 
For children, the above assumptions are the same, except: 
• Triple-drug therapy is given to children who are experiencing AIDS 
defining illnesses according to the Centre for Disease Control Clinical 
Staging System for Children or if their CD4 percentage is below 15 
percent. 
• In the first six months on treatment children have a 9.6 percent chance 
of death due to AIDS and a 13.7 percent chance of ceasing treatment 
due to adverse side effects.  
• In each subsequent year, children on antiretroviral treatment are 
assumed to experience an AIDS mortality rate of 11.4 percent, and a 
drop-out of 5.8 percent. 
 
These assumptions are based on an extensive analysis of HAART-related 
studies and the interested reader is referred to Johnson and Dorrington (2002) 
for more details.  To summarise, the outcome of these assumptions is that 
patients on HAART live longer and experience less morbidity (illness).  Each 
year, some patients on HAART either die or leave the programme and go 
back to the stage they were at the onset of HAART.     
 
 
Table 18: Prices of antiretroviral regimens 
Drug Costs Values Source 
Monthly Cost of 
First-line Treatment
R355 Price of AZT, Lamivudine, Nevirapine that MSF purchases 
from Brazil. 
Monthly Cost of 
Second-line 
Treatment 
R611 Price of Didanosine, Stavudine, Lopinavir, Ritonavir in 
South Africa October 2002 (This is the price  quoted by 
pharmaceutical manufacturers to the HIV/AIDS Clinicians 
Society. It excludes VAT and prescription fees. – source: 
Aid for AIDS)9 
Monthly Cost of 
Paediatric HAART 
R583 Communication with Dr Mark Cotton at Tygerberg 
Hospital – Paediatric HAART costs are highly variable 
across individuals, so an average price of R7000 per year 
has been used.  
 
 
Drug costs vary according to whether patients are on their first or second 
antiretroviral regimen (i.e. ‘first line’ or ‘second line’ treatment).  The 
number of patients on first and second line treatment is supplied by the 
                                          
9  This is based on communication with R. Wood and C. Orrell of Somerset Hospital. 
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antiretroviral module of the ASSA2000 Interventions Model.10  We assume 
that bioequivalent generic antiretrovirals at current best prices are available to 
the public sector.  Alternatives to this assumption are considered later.   
 
The distinction between first line and second line antiretroviral regiments has 
not been made in costing the treatment of children.  Prescriptions for children 
vary according to body weight, tolerance and whether paediatric or standard 
pharmaceutical formulations are used.  A single average cost of R7 000 (this 
rises to R7 350 once a ‘wastage’ factor is accounted for) per child per year 
for medicines has therefore been used.11  Monitoring methods and unit costs 
are assumed to be the same as those for the adult HAART programme. 
 
Monitoring costs per patient depend on the year of treatment of the patient.  
In our model the costs vary between the first and subsequent years because 
closer patient monitoring is necessary in the first year.  The monitoring costs 
include the costs of Lactate Dehydrogenase (LDH), CD4, Full Blood Count 
(FBC), Differential (Diff) and Amylase tests (see Table 19). 
 
 
Table 19: Frequency of monitoring tests for HAART and cost per 
monitoring test 
Monitoring Costs 
Tests Conducted Values Source 
No. of LDHs first year 7 
No. of CD4s first year 3 
No. of FBCs first year 7 
No. of Diffs first year 7 
No. of Amylase first year 7 
No. of LDHs subsequent years 4 
No. of CD4s subsequent years 2 
No. of FBCs subsequent years 4 
No. of Diffs subsequent years 4 
No. of Amylase subsequent years 4 
Communication with R. Wood and C. 
Orrell 
 
Cost of LDH  R26.00 
Cost of FBC  R57.00 
Cost of Diff R34.00 
Cost of Amylase R28.00 
Communication with NHLS/SAIMR 
 
 
                                          
10 The median period spent on first line treatment is slightly more than three years. 
11  This estimate is based on communication with M. Cotton, a paediatrician running the 
HAART programme at Tygerberg Hospital). 
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Table 20 summarises the assumptions about time spent by personnel with 
patients on HAART.  We relied heavily on information from Medecins Sans 
Frontieres (MSF) concerning their HAART programme in Khayelitsha. 
 
 
Table 20: Time spent by personnel with patients on HAART 
Personnel Time Spent With Patients  
Follow-up Rate After 1st visit 75% 
Subsequent Follow-up Rate 95% 
 
Session Length in First Year Nurses Doctors Counsellors 
1st Visit 30 minutes 1 hr 1 hr 
2nd Visit 15 minutes 30 minutes 30 minutes 
3rd Visit 15 minutes 15 minutes 45 minutes 
4th visit 15 minutes 15 minutes 45 minutes 
5th Visit 15 minutes 15 minutes 15 minutes 
Session Length in Subsequent Years 15 minutes  15 minutes  45 minutes  
Number of Sessions in First Year 5 4 5 
Number of Sessions in Subsequent 
Years 
4 4 2 
Admin Time per Session (nurse) 3 minutes   
Time spent on Drug Distribution per 
Patient per Year 
30 minutes   
Group Counselling    
Number Sessions First Year   8 
Number Sessions Subsequent Years   12 
Length of Session   2 hours 
Patients per Group   20 
Nurse Training   
Additional Training Factor (nurses) 10% Based on Interview with MSF 
*Based on the experience of MSF in Khayelitsha. 
 
 
We have assumed that patients in their first year of treatment are on a first-
line regimen.  There is a 20.6 percent chance of a patient moving to a second-
line regimen in each subsequent year.  For simplicity, once patients move to a 
second-line regimen, they are assumed to remain there until the ASSA2000 
Interventions Model removes them from the HAART programme.  
 
 
Table 21: Wastage and additional care assumptions in costing of 
HAART intervention 
Other Assumptions   
Factor Value Source 
Additional Care Factor 20% Communication with Wood and Orrell
Wastage Factor 5% Assumption  
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The information reported so far can be used to calculate the number of people 
in first and subsequent years of antiretroviral treatment.  These figures can 
then be multiplied by the cost per patient in first and subsequent years of 
treatment and added to the drug and monitoring costs to calculate a total cost 
for the programme.  Note that all calculations include a wastage factor.  A 
factor is also included to cater for patients who require additional care (e.g. 
due to serious side-effects, inadequate recovery, psychological factors, 
special medicine needs etc).  Table 22 provides details on the cost factors for 
paediatric HAART which differ from those in the adult programme.   
 
 
Table 22: Paediatric cost factors for HAART intervention 
Paediatric HAART Staffing  
Time spent per session (minutes) Values 
Doctor 45 
Nurse 30 
Admin (Nurse) 15 
Blood Test (Nurse) 20 
Number of Sessions (per year)  
Sick 1st Year 7 
Sick 2nd Year 3 




Costing the Intervention Scenarios 
 
The cost over time of the interventions under Scenarios Two (prevention 
interventions) and Three (prevention and treatment interventions) are 
presented in the tables below.  These costs exclude public education and 
certain infrastructure costs.12     
 
HAART is the intervention most beneficial to adults, but it is also the most 
expensive.  The cost of adult HAART dwarfs the other interventions.  It 
increases until 2015 when it peaks at R18.2 billion.  At this point 2.3 million 
adults receive HAART in the public sector (about 220 000 adults receive 
HAART through medical schemes).  The cost of HAART declines after 2015 
as the number of HIV-positive people falls (from about 6 million in 2015 to 
about 5 million in 2025). 
                                          
12 We include these costs later in the costing exercise.  
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Table 23: Direct cost to the Department of Health of treatment and 
prevention strategies for 2010 and 2015 for the non-medical scheme 
population (prices in Rands) 













VCT R21 million R17 million R16 million R13 million 
MTCTP R121 million R121 million R111 million R108 million 
STI R78 million R90 million R53 million R69 million 
Adult 
HAART 
Zero R15 billion Zero R18.2 billion 
Child 
HAART 
Zero R1.5 billion Zero R1.5 billion 
 
 
There is no sudden impact on the health budget because the implementation 
of the interventions is phased in (up to 90 percent).  Table 24 indicates that 
the cost implications of the implementation of HAART are gradual enough to 
prepare the necessary budget increases.  Table 25 presents the phased in costs 
for Scenario Two. 
 
 
Table 24: Cost of interventions under Scenario Three (treatment and 
prevention) from 2002 to 2007 in millions of Rands 
  2002      2003 2004 2005 2006 2007
MTCTP R 50 R 82 R 112 R 133 R 137 R 133 
VCT R 9 R 14 R 20 R 25 R 25 R 23 
Adult HAART R 226 R 966 R 2,325 R 4,348 R 6,816 R 9,289 
Paediatric HAART R 53 R 198 R 409 R 663 R 921 R 1,134 




Table 25: Cost of interventions under Scenario Two (prevention) from 
2002 to 2007 in millions of Rands 
  2002      2003 2004 2005 2006 2007
MTCTP R 50 R 82 R 112 R 132 R 136 R 131 
VCT R 9 R 14 R 20 R 26 R 27 R 26 
STI R 166 R 165 R 158 R 146 R 130 R 114 
 17
Including Viral Load Tests 
 
The above costing of adult and paediatric HAART interventions omits viral 
load tests.  According to the WHO guidelines (World Health Organisation, 
2002a), viral load tests are optional because of resource constraints. 
However, given the benefits of using viral load tests to monitor patients, we 
have extended the cost calculation to include them (see Table 26).  Currently, 
MSF pays R625 per viral load test.  This means that the combined price of 
CD4 and viral loads tests is R707.40.  Recently, at least two laboratories have 
begun offering CD4 and viral load tests for R500 – so these costs can be 
expected to fall.   
 
 
Table 26: Cost of HAART when viral load tests are included 
 2007   2010 2015
Paediatric 
HAART 
R1.3 billion R1.7 billion R1.7 billion R500 for CD4 
and Viral 
Load Adult HAART R10.9 
billion 
R17.4 billion R20.8 billion 
Paediatric 
HAART 
R1.4 billion R1.8 billion R1.8 billion R707.40 for 
CD4 and Viral 
Load Adult HAART R11.7 
billion 




Cost of Infrastructure and Public Education  
 
Our costing of the HAART intervention has yet to include health-care 
infrastructure costs (such as building counselling rooms for the VCT 
intervention, technical assistance and office expenses for site co-ordinators).  
It also excludes public education and outreach programmes designed to 
popularise the interventions and increase their uptake.   
 
This section provides an estimate of such costs for all the interventions.  We 
base these primarily on information available from various MTCTP pilot 
projects (as this is the best data available on intervention-related 
infrastructural and other costs).  Note that our analysis here does not take into 
account that many of these costs could be shared by the different 
interventions and therefore our calculated costs in this section are probably 




Table 27: Components of additional infrastructure and public 
education costs 
Infrastructure and Public 
Education 
Start-up Annualised Source 
Counselling Room per Site R50,000 R10,000 Communication with 
Western Cape 
Department of Health 
Community Meetings per Site R9,500  
Recruitment of Educators per Site  R5,000 
Training Educators per Site  R15,000 
Educator Salaries per Site R11,538 R180,000 
Materials per Site  R5,000 
Office Expenses of the 
Coordinator 
R6,200 R24,000 
Technical Assistance per Site R30,769 R9,231 
Recruitment of Coordinator  R25,700  
Coordinator Salary R67,500 R135,000 
Coordinators per Site  1 





The additional intervention infrastructure cost is composed as follows:  a co-
ordinator per site, office expenses for the co-ordinator, technical assistance 
costs and counselling rooms for the intervention sites.13  The public education 
cost is composed of the costs of community meetings, the employment of 
educators and the purchase of materials.  These are all based on information 
from MTCTP intervention sites.  Table 27 summarises this information, and 
Table 28 provides a total cost estimate (phased in) based on these additional 
costs.   
 
We have assumed that the additional infrastructure and public education costs 
per patient for MTCTP can be projected as the cost per patient for other 
interventions (except the STI intervention because the recommended changes 
do not require extensive additional expenditure on infrastructure and public 
education).  Our public education costs are probably too high because civil 
society organisations that specialise in outreach – and which are not 
predominantly state funded – can be expected to absorb a substantial part of 
this cost.  
 
 
                                          
13 We did not include these co-ordinator related costs in the earlier costing for the MTCTP 
programme (so there is no double-counting).  
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Table 28: Additional cost to MTCTP intervention in millions of Rands 
when education and additional infrastructure specific to the 
programme are included for Scenario Three 
  2002      2003 2004 2005 2006 2007
Education R 13 R 21 R 29 R 34 R 35 R 35 
Infrastructure R 18 R 25 R 32 R 35 R 33 R 32 




The combined infrastructure and educational cost per individual benefiting 
from an intervention in Scenario Three peaks at approximately R85 per year.  





        
Table 29: Cost in millions of Rands of education and infrastructure for 
Scenario Three 
  2002 2003 2004 2005 2006 2007 2010 2015
Education R 105 R 164 R 216 R 248 R 252 R 246 R 243 R 232 
Infrastructure R 21 R 34 R 51 R 69 R 81 R 89 R 119 R 133 
Total R 126 R 198 R 268 R 317 R 332 R 336 R 362 R 365 
 
 
Cost of Condom Distribution 
 
VCT programmes will be more successful if they include a safer-sex 
component which emphasises condom use (Voluntary HIV-1 Counselling 
and Testing Efficacy Study Group, 2000).  Using the Voluntary HIV-1 
Counselling and Testing Efficacy Study Group results, Johnson and 
Dorrington (2002) assume 25 condoms are distributed to patients receiving 
VCT.  We assume that the VCT and MTCTP programmes distribute 
condoms out of the existing government stock, and therefore no additional 
costs relating to condom distribution are included.  It is possible, however, 
that this more targeted condom distribution will result in greater demand for 
condoms by the public sector.  The state tender price for condoms is R0.25 
per male condom and R1.17 per female condom (personal communication, 
Department of Health).  If we make the (implausible) assumption that the 
condoms distributed in the VCT and MTCTP interventions are over and 
above the stock that the government usually distributes, then the additional 
cost would be negligible; less than R8 million at the peak of the epidemic.   
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Cost of Medicines 
 
As stressed earlier, the cost of antiretroviral medicines is the largest 
component of adult HAART.  The following analysis demonstrates the effect 
on the costing of adult HAART of different medicine prices.  In the analysis 
presented earlier, we considered both patented brand-name antiretroviral 
medicines and bioequivalent generics.  In this section, we present three other 
options: 1) only patented medicines are used at the best prices that have been 
offered around the world; 2) transposing the first- and second-line medication 
regimens (which results in a cheaper first-line regimen and a more expensive 
second-line regimen) and; 3) the prices of generic or brand-name medicines 
drops to R300 for a first-line regimen and R450 for a second-line regimen.  
 
This assumed decrease in price of medications is realistic when one 
considers: a) that there are already first-line generic regimens below R300 
including one that has been approved by the World Health Organisation; and 
b) that there will be economies of scale generated by the South African 
epidemic.  In particular, the Department of Health would have considerable 
negotiating power for lower medicine prices if it opted to provide 
antiretrovirals on a large scale.   
 
 
Table 30: Different drug prices used to cost adult HAART 
Medicine Price 
Option 
First-line   Second-line Monthly price


























Not applicable Not applicable R300 R450 
Patented prices 


























When examining medicine prices, we used regimens recommended by the 
WHO (World Health Organisation 2002a).  This resulted in the second-line 
regimen being cheaper than the first-line regimen because the patented 
versions of Didanosine and Stavudine (recommended for second-line use) are 
much cheaper than the patented versions of AZT and Lamivudine 
(recommended for first-line use).  In this section, we consider the cost of 
adult HAART for patented medicines only where AZT and Lamivudine is 
used as the first-line regimen in one costing exercise, and as the second-line 
regimen in another. 
 
 
Table 31:  Cost of adult HAART in 2015 under different pricing options 





Total cost in 
2015 
1 Best current prices 
(generics and patented 
medicines) 
R6,413 R1,464 R18.2 billion 
2 Alternative regimen at best 
current prices (generics and 
patented medicines) 
R7,088 R1,464 R19.8 billion 
3 R300 for first-line and 
R450 for second-line 
R4,917 R1,464 R14.7 billion 
4 Best patented prices 
(AZT/Lamivudine in first-
line) 
R9,190 R1,464 R24.6 billion 
5 Best patented prices 
(Didanosine. Stavudine in 
first-line) 




Although using patented AZT and Lamivudine as a second-line (option 4 in 
Table 31) is cheaper than using it as a first-line (option 5) in 2015, this is 
only because by 2015 more patients will be on the second-line regimen.  
Spread over time, the medically optimal regimen is much more expensive.  
For example, in 2007 the sub-optimal patented regimen is R13.4 billion 
versus R15.6 billion for the optimal regimen. 
 
For the same reason, the alternative regimen (option 2 in Table 31) at best 
current prices is also more expensive than the WHO recommended regimen 
(option 1) in 2015, but is marginally cheaper in the phasing-in stage of the 
programme up to 2007.  Option 2 starts off with an average drug cost per 
patient per year of R4 243, but escalates to R7 088 per patient per year in 
2015, because of the increasing numbers of patients on second-line regimens. 
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Sometimes the regimens considered here are inappropriate for a patient.  For 
example, patients using Nevirapine might experience hepatoxicity and have 
to switch to Efavirenz, which at this time is slightly more expensive than 
Nevirapine.  However, the 20 percent additional patient care factor discussed 
previously has been included to cover this.  
 
 
Savings Incurred in Scenario Three (Prevention and 
Treatment) 
 
Scenario Three has the greatest benefits in terms of reduced mortality, 
reduced morbidity and reduction of new infections.  It also has a wide range 
of socio-economic benefits which include: reduced sick-leave; higher 
productivity, fewer days taken off for employees to attend funerals; lower 
employee replacement costs; preservation of human capital (such as nurses, 
teachers and educated high school students) and fewer orphans (Nattrass, 
2002).  We have not attempted here to estimate these wider benefits.    
 
But from the narrow perspective of the Department of Health’s budget, the 
costs of introducing the full range of treatment and prevention programmes 
appears substantial (even prohibitive) at the peak of the epidemic.   However, 
as argued below, prevention and treatment programmes entail both costs and 
savings for the public health sector.  These savings need to be considered in 
order to obtain an understanding of the net costs of prevention and treatment 
programmes.   In this section, we point to the financial savings (mainly due to 
lower hospitalisation requirements) implied by Scenario Three.  We also 
point to potential savings for the state due to lower orphans.    
 
 
Savings on Hospitalisation Costs 
 
When HAART is commenced under the conditions modelled here, there is a 
significant reduction in morbidity resulting in lower hospitalisation costs.  
The in- and out-patient hospitalisation costs of people in each clinical stage 
of HIV has been estimated by Kinghorn et al. (1996) for Baragwanath 
Hospital.  We rely on these estimates (suitably adjusted for inflation).  Since 
they were made six years ago and for one health institution only, the results 
in this section must be treated with caution.    
 
The ASSA2000 Interventions Model estimates the number of people in each 
stage of the disease. This information is then used to calculate the 
hospitalisation costs for each scenario.  The model also provides information 
on the number of people on antiretrovirals who are still in Stage Four (AIDS-
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sick), and the number of people on antiretrovirals who have become healthy.  
The assumption is made that people whose immune systems have been 
reconstituted (through HAART) have the same hospitalisation costs as those 
in Stage One (other than the costs of the HAART programme).  Given the 
absence of better data, we use the Kinghorn et al. (1996) estimates for 
children as well.  Table 32 lists the hospitalisation costs per HIV-positive 
patient in a given WHO stage per year. 
 
 
Table 32: Hospitalisation costs for patients with HIV 
Stage Cost per patient per year 
Adult Stage One R1,378 
Adult Stage Two R1,378 
Adult Stage Three R6,572 
Adult with AIDS R18,020 
Adult on HAART who has become healthy again R1,378 
Child pre-AIDS R1,378 
Child with AIDS R18,020 
 
 
Table 33 shows the hospitalisation costs of people with HIV assuming that 
everyone who requires treatment for an opportunistic infection receives it.  
 
 
Table 33:  Costs in billions of Rands of public hospitalisation for 
people with HIV under the three scenarios 
  2002        2003 2004 2005 2006 2007 2010 2015
Scenario 
One 
24 28 31 34 36 37 36 32 
Scenario 
Two 
24 27 31 34 35 36 35 27 
Scenario 
Three 




The 2002/03 health budget is R33.981 billion (National Treasury, 2002).  The 
AIDS-related hospitalisation costs we project for 2002 are approximately 71 
percent of the budget. Assuming the health budget remains the same in real 
terms14 hospitalisation costs for HIV patients in Scenario One eventually 
exceed the health budget.  
 
                                          
14 There has been a per capita decrease in health expenditure over the last eight years. 
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A Department of Health report states: 
 “The largest single impact of HIV/AIDS on the public health 
sector lies in the hospital sector. Research commissioned by the 
Department of Health indicates that, in the year 2000 an estimated 
628,000 admissions to public hospitals were for AIDS-related 
illnesses, which amount to 24 percent of all public hospital 
admissions. Modelling indicates very clearly that, as more people 
who are already HIV-positive become sick each year, this demand 
for hospitalisation will increase steadily every year in the absence 
of significant alternative interventions.  In financial terms, the cost 
of hospitalising AIDS patients in public facilities is already likely 
to be at least R3.6 billion in the current financial year, or 12.5 
percent of the total public health budget” (Department of Health, 
2001, p. 3).  
 
The Department of Health only spent R3.6 billion on in-patient AIDS 
hospitalisations in 2000. Our estimate of the actual in- and out-patient 
hospitalisation needs for 2000 is R13.6 billion.  Yet according to the 
Department of Health, only R3.6 billion was spent on in- and out-patient 
hospitalisations in 2000.  How do we reconcile this information?  If we 
assume that patient-cost estimates and the Department of Health’s facts are 
accurate, then either a substantial number of AIDS-related illnesses are not 
being presented at hospitals (people are not attempting to get treated) or a 
high level of patient rationing is taking place in the public health sector.   
 
According to the numbers estimated by Kinghorn et al. (1996), the cost of 
out-patient care range from less than 10 percent of hospitalisation costs for 
patients in Stage Four to approximately 47 percent of costs for patients in 
Stage One and Two. Assuming the higher range for out-patient costs (i.e. 47 
percent), the upper limit on the cost of in- and out- hospitalisation costs on 
people with HIV in 2000 is R6.7 billion, or 24 percent of the health budget 
for 2000.  The implication is that the health budget was at least R6.9 billion, 
but probably much closer to R10 billion, short of the amount necessary to 
provide treatment to all who need it and to avoid rationing of HIV patients.   
 
It must be emphasised that the above estimates are rough approximations, 
because of the large number of assumptions that underpin them.  However, 
the margin of error would have to be enormous to render inaccurate the 
conclusion that South Africa is failing to provide adequate health care to the 




Additional cost of public 
hospitalisation in scenario one and 


































Figure 3: Additional expenditure in hospitalisation costs in Scenarios 
One and Two over Scenario Three 
 
 
While some rationing is bound to occur, even in a very good health-care 
system,15 the level of rationing that is probably occurring implies that current 
Government health-care policy objectives are not being realised.  It is 
probable that many patients who use the public sector are getting sub-optimal 
treatment irrespective of their HIV-status.  This correlates with descriptions 
of a public health-care infrastructure under enormous pressure (South African 
Health Review, 2002).  High levels of rationing will probably continue in all 
three scenarios unless per capita health expenditure is increased to 
compensate for the shortfall.  
 
Up until now, Scenario One has essentially been government policy, but even 
this limited policy objective (of treating OIs), is not being met.  We have 
calculated the savings that Scenario Three generates in hospitalisation costs 
by assuming that the government meets its policy obligations and that no 
rationing takes place.  This is depicted in Figure 3. Note that per capita 
savings would be even more significant, because of the additional population 
still alive in Scenario Three.16 
                                          
15 Recall that the interventions all assume 10% rationing once fully implemented. 
16 ASSA2000 predicts a population of 46.8 million in Scenario One and 49.6 million 
people in Scenario Three in 2015. This amounts to approximate expenditures of R524 per 
person in Scenario Three versus R684 per person in Scenario One.  
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While these savings do not fully compensate for the additional direct 
financial cost to the Department of Health of Scenario Three, they 
demonstrate that the additional money spent in Scenario Three will reduce 
rationing and alleviate pressure on the public health system.  
 
 
Savings on Orphan Costs 
 
The ASSA2000 Interventions Model projects the number of double-orphans17 
in Scenario One and in a (simplified) version of Scenario Three where only 
VCT and HAART are implemented.  Figure 4 shows that the difference 
between the scenarios becomes greater over time, culminating with Scenario 
Three having nearly one million fewer additional orphans in 2015.   
 
Government expenditure on orphans is primarily on foster care grants and 
subsidies to children’s homes.  Fewer orphans implies greater savings on 
these grants and subsidies.  However, due partially to administrative 
inefficiencies, many orphans living with guardians other than their parents do 
not receive a subsidy.  Black Sash calculates the take-up rate of the foster-
care grant as 36.7 percent (communication with Karen Kallmann of Black 
Sash, 2002).  Further complexities that have to be considered when 
calculating implications of the different scenarios for such welfare spending 
include: 
• Some children who become eligible for the foster care grant may have 
been previously receiving the child support grant (i.e. when their parents 
were alive).  
• Some children who are eligible for the foster care grant receive a child 
support grant instead, because it is easier for the foster parents to apply 
for this. 
• Some children whose mothers have died are effectively orphans 
because their fathers are absent.  They might be eligible for foster care 
grants or a state subsidy if they are placed in children’s homes. 
• A small, possibly insignificant, percentage of orphans will not be 
eligible for a grant or subsidy because of independent incomes. 
• Some children are eligible for placement in children’s homes when 
their parents have not yet died because the parents’ morbidity renders 
them unable to fulfil their parental obligations. 
• The administrative costs of placing children in foster-care and 
children’s homes might be large and therefore need to be considered.  
 
                                          
17 Double-orphans are defined here as children under 18 whose parents have both died. 
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Number of double-orphans under scenario one 


































Figure 4: Number of double-orphans produced under Scenario One 
and simplified Scenario Three (only VCT and HAART implemented in 
simplified Scenario Three) 
 
 
As of April 2002, the foster care grant was R450 per month and the child 
support grant, R130 per month.  The government subsidy for children’s 
homes in KwaZulu-Natal is R1 000 per child per month (personal 
communication with Pinetown Child Welfare). 
 
Estimating the effect of additional orphans under Scenarios One and Two 
over Scenario Three would be a useful research project. The savings to the 
state under Scenario Three due to lower orphan costs are likely to be large. 
The following simple calculation gives a lower bound estimate of the cost of 
orphan grants in 2015, assuming that the current level of take up of foster 
care grants remains stable.  
 
• In 2015, the ASSA2000 interventions model estimates that the 
simplified version of Scenario Three has 927 000 fewer orphans than 
Scenario One.  
• Approximately 340 000 children take up a foster care grant (or live in 
government-funded children’s homes, but since this is more expensive, 
we assume that all receive the foster care grant for the purposes of 
calculating a lower bound). 
• We further assume that the 927 000 fewer orphans in Scenario Three 
are all eligible for child support grant, but that the uptake rate of this 
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grant is equivalent to the current uptake rate (52.8 percent according to 
Black Sash). 
 
This calculation yields a saving of over R1 billion in 2015 in Scenario Three 
over Scenario One. It must be emphasised that this is a very conservative 
estimate of the lower bound of savings.  When the other factors described 
above are taken into account and a more accurate analysis is done, the 
calculated savings will be considerably higher.  Furthermore, the current 
uptake rate of the foster care grant is inadequate.  If the state becomes more 
efficient at meeting its policy obligations towards orphans, the additional cost 
of orphan care would become extremely large under Scenario One. 
 
 
The Direct Cost of Scenario Three as a Percentage of 
GNP 
 
Table 34 presents the total direct cost of Scenario Three (i.e. excluding the 
savings discussed above) as a percent of the South African Gross National 
Product (GNP).18    
 
 
Table 34: Total cost of Scenario Three (including infrastructure and 
education) in billions of Rands and as a percentage of GNP 
Year         2002 2003 2004 2005 2006 2007 2010 2015
Scenario Three 
(R billion) 
0.6 1.6 3.3 5.6 8.4 11.0 17.1 20.3 
GNP (R billion) 1 012 1 033 1 053 1 074 1 096 1 118 1 140 1 163 
Scenario Three as 
% of GNP 
0.06% 0.16% 0.31% 0.52% 0.76% 0.99% 1.50% 1.74% 
 GNP Data from the South African Reserve Bank 
 
 
The recently published report on the Commission on Macroeconomics and 
Health commissioned by the WHO states, “We believe that it is feasible, on 
average, for low- and middle-income countries to increase budgetary outlays 
for health by 1 percent of GNP by 2007 and 2 percent of GNP by 2015 
compared with current levels, though this may be optimistic given intense 
competing demands for scarce public resources” (World Health Organisation, 
2002b: 6).  
                                          
18 The GNP for the third quarter of 2001 through to the end of the second quarter of 2002 
was R993 billion at current prices (South African Reserve Bank, 2002).  The 
corresponding ASSA2000 time period is 2001 (ASSA2000 years run from July to June).  
We assume a modest real growth rate of 2 percent per annum for the GNP.  
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Scenario Three easily fits within the range of additional spending 
recommended by the Commission.  If the cost of antiretroviral medicines can 
be brought down to R300 per first-line regimen and R450 per second-line 
regimen for adult HAART, the cost of Scenario Three drops to 1.44 percent 
of GNP in 2015.  Even if a zero percent growth rate is assumed until 2015, 
the cost of Scenario Three escalates to 2.04 percent of GNP in 2015 assuming 
current generic medicine prices or 1.69 percent of GNP for the lower-price 
estimate.    
 
There are, of course, health interventions other than those listed in Scenario 
Three which are also not yet provided by the Department of Health.  But 
these are unlikely to be of the same order of magnitude as Scenario Three and 
therefore unlikely, when combined with Scenario Three, to push health 
expenditure beyond prudent levels. 
 
The burden on the health-care budget of Scenario Three can be reduced in a 
number of ways.  As has already been shown, bringing medicine prices down 
to R300 for a first-line regimen and to R450 for a second-line regimen would 
significantly alleviate the financial burden. The burden can be further 
alleviated by: 1)  using funds from the recently established Global Fund to 
Fight AIDS, Tuberculosis and Malaria; 2) negotiating with pharmaceutical 
companies to lower antiretroviral prices in the private sector so that more 
people can purchase their medicines privately instead of using the public 
system;  3) encouraging the medical scheme industry to increase the size of 
their membership;19 4) encouraging more employers to offer antiretroviral 
therapy to their employees; and 5) charging a reasonable fee proportional to 





The key conclusions of this analysis are: 
• Of the three scenarios examined, Scenario Three (treatment and 
prevention) provides significant benefits for the population, but also requires 
the largest budget.  However, if savings due to lower morbidity (reflected in 
fewer hospitalisations) and fewer orphans are offset against the extra direct 
expenditure required in Scenario Three, then the net cost to government is 
substantially lower.  
• The combined direct cost of the interventions in Scenario Three at the peak 
of the epidemic (in 2015) is approximately R20 billion (including 
infrastructure and education costs).  The savings in expenditure to which the 
                                          
19 Currently, about 16% of the South Africans are on medical schemes.   
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Government has legally committed itself (i.e. hospitalisation and orphan 
costs) would be a minimum of R7 billion. 
• The price of antiretroviral medicines is the most significant factor in the 
cost of Adult HAART and consequently the most significant factor in the 
cost of Scenario Three.  The price difference between best-priced patented 
medicines and generic versions is substantial.  If the prices of antiretrovirals 
are brought down to R300 per patient per month for first line regimens and 
R450 per patient for second-line regimen, the cost of Adult HAART is 
estimated to come down by nearly R4 billion for 2015.  
• Scenario One (i.e. no treatment and intervention programmes) is costly 
both in terms of human lives, and in terms of hospitalisation costs (associated 
with treating opportunistic infections).  Scenario Two (prevention) is 
substantially better on both scores, but not as effective as Scenario Three.   
• Our modelling of Scenario Three (treatment and prevention) does not 
entail a sudden massive increase in the health-budget.  We show that it can be 
implemented gradually so that an unmanageable burden is not placed on the 
government budget.  The cost of Scenario Three peaks in 2015 and gradually 
drops and levels off after that.  The additional expenditure required by 
Scenario Three expressed as a percentage of GNP is within the recommended 
guidelines of the WHO.   
• Irrespective of which scenario is implemented, the government has to 
increase substantially per capita spending on health and social welfare if it is 
to cater for the requirements of needy people.  The health budget appears to 
be too small already to meet the health needs of the population – irrespective 
of HIV status.   
• Further research is needed into hospitalisation and orphan costs. Home-
based care and post-exposure prophylaxis have not been considered in this 
analysis – but are important interventions that need to be researched.  New 
research on the effect of HAART on reducing the incidence of HIV-related 
Tuberculosis also needs to be considered (Wood et al., 2002). 
• The implementation of Scenario Two or Scenario Three, or even 
eliminating rationing in Scenario One, will require adequate planning, 
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The Centre for Social Science Research 
 
The CSSR is an umbrella organisation comprising five units:  
 
The Aids and Society Research Unit (ASRU) supports quantitative 
and qualitative research into the social and economic impact of 
the HIV pandemic in Southern Africa.  Focus areas include:  the 
economics of reducing mother to child transmission of HIV, the 
impact of HIV on firms and households; and psychological 
aspects of HIV infection and prevention.  ASRU operates an 
outreach programme in Khayelitsha (the Memory Box Project) 
which provides training and counselling for HIV positive people 
 
The Data First Resource Unit (‘Data First’) provides training and 
resources for research.  Its main functions are: 1) to provide 
access to digital data resources and specialised published 
material; 2) to facilitate the collection, exchange and use of data 
sets on a collaborative basis; 3) to provide basic and advanced 
training in data analysis; 4) the ongoing development of a web 
site to disseminate data and research output.    
 
The Democracy In Africa Research Unit (DARU) supports students 
and scholars who conduct systematic research in the following 
three areas:  1) public opinion and political culture in Africa and 
its role in democratisation and consolidation; 2) elections and 
voting in Africa; and 3) the impact of the HIV/AIDS pandemic on 
democratisation in Southern Africa. DARU has developed close 
working relationships with projects such as the Afrobarometer (a 
cross national survey of public opinion in fifteen African countries), 
the Comparative National Elections Project, and the Health 
Economics and AIDS Research Unit at the University of Natal. 
 
The Social Surveys Unit (SSU) promotes critical analysis of the 
methodology, ethics and results of South African social science 
research. One core activity is the Cape Area Panel Study of 
young adults in Cape Town.  This study follows 4800 young people 
as they move from school into the labour market and adulthood.  
The SSU is also planning a survey for 2004 on aspects of social 
capital, crime, and attitudes toward inequality. 
 
The Southern Africa Labour and Development Research Unit 
(SALDRU) was established in 1975 as part of the School of 
Economics and joined the CSSR in 2002.  SALDRU conducted the 
first national household survey in 1993 (the Project for Statistics on 
Living Standards and Development).  More recently, SALDRU ran 
the Langeberg Integrated Family survey (1999) and the 
Khayelitsha/Mitchell’s Plain Survey (2000).  Current projects 
include research on public works programmes, poverty and 
inequality.  
 
 
 
 
